(603205)"JIANERKANG MEDICAL CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 603205 · · 12 pages · Chinese
Summary by 6ix AI
The report includes significant financial metrics such as revenue and net profit, along with changes in these figures compared to the previous year. Additionally, the report emphasizes the responsibilities of the board and management regarding the accuracy and completeness of the information presented.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Jianerkang Medical Co. Ltd. on 6ix
Earlier from Jianerkang Medical
- Announcement on Redemption upon Maturity of Cash Management Products Purchased with Certain Idle Raised Funds
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Semi-annual Report for 2026
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on Redemption at Maturity of Partial Idle Raised Funds Used for Cash Management
Later from Jianerkang Medical
- (603205)"JIANERKANG MEDICAL CO., LTD."Announcement on Completion of Election of New Board of Directors and Appointment of Senior Executives and Securities Affairs Representative
- (603205)"JIANERKANG MEDICAL CO., LTD."Announcement on Convening the Q3 2026 Performance Briefing
- (603205)"JIANERKANG MEDICAL CO., LTD."Announcement on Election of Employee Representative Director for the 3rd Board of Directors
- (603205)"JIANERKANG MEDICAL CO., LTD."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- (603205)"JIANERKANG MEDICAL CO., LTD."Announcement on Resolutions of the 1st Meeting of the 3rd Board of Directors
Follow Jianerkang Medical into a list and get an email when it puts out news.
Follow Jianerkang Medical